Exscientia Ltd ADR

NASDAQ EXAI

Data sourced from

and

Download Data

Exscientia Ltd ADR Debt to Capital Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending December 31, 2023: 33.53%

Exscientia Ltd ADR Debt to Capital Ratio 2 year CAGR is 33.53% for the Trailing 12 Months (TTM) ending December 31, 2023. The debt to capital ratio measures the proportion of a company's total capitalization that is financed by debt. It is calculated by dividing total debt by the sum of total debt and shareholders' equity. This ratio provides insights into the capital structure and financial risk of the company. A higher ratio indicates a greater reliance on debt financing. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Exscientia Ltd ADR Debt to Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.01, a 39.06% change year over year.
Exscientia Ltd ADR Debt to Capital Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.00.

NASDAQ: EXAI

Exscientia Ltd ADR

CEO	Prof. Andrew L. Hopkins DPHIL, FRSE FRSC
IPO Date	Oct. 1, 2021
Location	United Kingdom
Headquarters	The SchrOedinger Building, Oxford, United Kingdom, OX4 4GE
Employees	483
Sector	Healthcare
Industry	Biotechnology

Description

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Key trends